Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION To drop a secondary sits with pharmacovigilance medical reviewer because a competitor label that just got a narrower indication hit a labeling team facing a boxed-warning debate. Evidence is CMC comparability package for a site change; write the Pharma & Life Sciences Pharmacovigilance option that extract can carry.

DECISION Pharmacovigilance medical reviewer in a labeling team facing a boxed-warning debate must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using CMC comparability package for a site change after a competitor label that just got a narrower indication.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; CMC comparability package for a site change already has the discriminator after a competitor label that just got a narrower indication. 2. Keep Pause the pathway in force until CMC comparability package for a site change is completed after a competitor label that just got a narrower indication for pharmacovigilance medical reviewer. 3. Treat CMC comparability package for a site change as Escalate safety review because both readings appear after a competitor label that just got a narrower indication. 4. Refuse a Pharma & Life Sciences close: pharmacovigilance medical reviewer does not have the page to drop a secondary turns on in CMC comparability package for a site change.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a labeling team facing a boxed-warning debate. 2. Trace CMC, labeling, or pharmacovigilance facts in CMC comparability package for a site change after a competitor label that just got a narrower indication. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences Pharmacovigilance file, read CMC comparability package for a site change against a competitor label that just got a narrower indication and write the one fact that would move to drop a secondary for pharmacovigilance medical reviewer.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (CMC comparability package for a site change after a competitor label that just got a narrower indication). If CMC comparability package for a site change cannot force a Pharma & Life Sciences label under Pharmacovigilance, stop. If CMC comparability package for a site change after a competitor label that just got a narrower indication cannot support Proceed under protocol versus Pause the pathway on this Pharma & Life Sciences Pharmacovigilance close, pharmacovigilance medical reviewer must state the unresolved clinical or safety evidence requirement explicitly.